ReviewMolecules (Basel, Switzerland)2019
Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma.
Review in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Innovative Designs of Multimodal Imaging Based on Radionuclide, Quantum, and Cargo-Loaded Nanoplatform Emitters Towards Enhanced Energy-Matter Interactions for Photonics and Bioassays.Materials (Basel, Switzerland) · 2026Review
- Advances in Functional and Metabolic Imaging for Early Tumor Treatment Response and Resistance Evaluation: A Review.Cancers · 2026Review
- Non-[Pharmaceuticals (Basel, Switzerland) · 2024Review
- Radiopharmaceuticals for Skeletal Muscle PET Imaging.International journal of molecular sciences · 2024Review
- Article
- Multitracer PET/CT with [Diagnostics (Basel, Switzerland) · 2023Article
- Recent developments on the application of molecular probes in multiple myeloma: Beyond [Frontiers in bioengineering and biotechnology · 2022Review
- Imaging for Plasma Cell Dyscrasias: What, When, and How?Frontiers in oncology · 2022Review
- Molecular Imaging in Multiple Myeloma-Novel PET Radiotracers Improve Patient Management and Guide Therapy.Frontiers in nuclear medicine · 2022Review
- Editorial: Molecular Imaging in Multiple Myeloma: An Update and Future Perspectives.Frontiers in nuclear medicine · 2022Article
- [Positron emission tomography/computed tomography (PET/CT) in multiple myeloma].Der Radiologe · 2022Review
- The prognostic significance of [EJNMMI research · 2021Article
- In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [EJNMMI research · 2021Article
- Quantitative, DynamicDiagnostics (Basel, Switzerland) · 2021Article
- Case series: MRD negativity assessment usingTherapeutic advances in hematology · 2021Article
- CanCancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is a plasma cell disorder, characterized by clonal proliferation of malignant plasma cells in the bone marrow. Bone disease is the most frequent feature and an end-organ defining indicator of MM. In this context, imaging plays a pivotal role in the management of the malignancy. For several decades whole-body X-ray survey (WBXR) has been applied for the diagnosis and staging of bone disease in MM. However, the serious drawbacks of WBXR have led to its gradual replacement from novel imaging modalities, such as computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT). PET/CT, with the tracer
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.